Monoclonal Anti-TRANCE antibody produced in mouse
SIGMA/T2942 - clone 70525, purified immunoglobulin, lyophilized powder
MDL Number: MFCD02263998
Product Type: Chemical
| antibody form | purified immunoglobulin |
| antibody product type | primary antibodies |
| biological source | mouse |
| clone | 70525, monoclonal |
| conjugate | unconjugated |
| form | lyophilized powder |
| isotype | IgG2b |
| Quality Level | 100  |
| species reactivity | human |
| storage temp. | −20°C |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 8-25 μg/mL |
| UniProt accession no. | O14788  |
| Application: | Anti-TRANCE antibody may be used for immunohistochemistry of paraffin-embedded tissue sections at a working concentration of 8-25 μg/ml. For ELISA a concentration of 0.5-1.0 μg/ml is recommended. The antibody is also suitable for neutralization reactions (ND50 is 0.02-0.06 μg/ml). |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | TRANCE (TNF-related activation-induced cytokine), also called RANKL (RANK ligand), OPGL (Osteoprotegrin ligand), and ODF (Osteoclast differentiation factor) is a member of tumor necrosis factor superfamily that is expressed on the surface of osteoblasts and is released by activated T cells. When TRANCE binds to its receptor RANK it stimulates the formation, activation, survival and adherence of osteoclasts that increases the bone resorption. These effects are inhibited when RANKL binds to OPG that leads to decrease in bone resorption process and increase in bone volume and density. The TRANCE (RANKL)/RANK/OPG collectively activates NF-κB, JNK, Akt, p38, ERK, NFATc1 pathways. This axis is vital for maintaining the bone density, dendritic cell survival, B cell differentiation, mammary gland development. This signaling pathway maintains the osteoclast biology and is a therapeutic target for osteoporosis. Monoclonal Anti-TRANCE antibody recognizes human TRANCE (~27 kDa). This antibody demonstrates 5% cross reactivity with recombinant mouse TRANCE. |
| Immunogen: | recombinant human TRANCE |
| Physical form: | Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline with 5% trehalose. |
| Specificity: | The antibody show <5% cross-reactivity with recombinant mouse TRANCE. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 51111800 |